SEQENS R&D Center in Porcheville, France, confirms its status as a center of excellence

On 21 January 2019, the French National Agency for the Safety of Medicines and Health Products (ANSM) delivered the GMP (Good Manufacturing Practice) certificate to SEQENS R&D Center in Porcheville (near Paris) in France, after the first inspection, which confirms the authorization obtained in April 2018.

This certification is fully in line with the approach launched by SEQENS group in 2017 to make Porcheville R&D center the R&D platform of the group, in order to support the development and industrialization of pharmaceutical synthesis projects of the Group and its customers.
Porcheville R&D center, close to Paris, offers a use-area of over 2 000 m2 along with the cutting-edge equipment required to develop the most complex molecules in an environment perfectly in accordance with good manufacturing practices. With 13 cbm of reactors on 2 pilot units and 4 kilo-labs, our 100 scientists and experts on site develop tailor-made solutions for our customers and ensure that products are successfully transferred into production. Our researchers work together to provide the appropriate pharmaceutical intermediates and APIs for clinical studies with quality documentation and data for successful regulatory submission.

“This certification rewards the daily work of our employees to meet the highest standard of reliability and quality for all our customers. Our ambition is to continue to develop and produce the most complex molecules thanks to our recognized expertise and the widest continuum of technologies available on the market”, says Christophe Eychenne-Baron, SEQENS R&D Director.